Tavakol Shima, Zahmatkeshan Masoumeh, Mohammadinejad Reza, Mehrzadi Saeed, Joghataei Mohammad T, Alavijeh Mo S, Seifalian Alexander
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Pharmidex Pharmaceutical Services Ltd., London, United Kingdom.
Heliyon. 2021 Apr;7(4):e06841. doi: 10.1016/j.heliyon.2021.e06841. Epub 2021 Apr 15.
COVID-19 has recently become one of the most challenging pandemics of the last century with deadly outcomes and a high rate of reproduction number. It emphasizes the critical need for the designing of efficient vaccines to prevent virus infection, early and fast diagnosis by the high sensitivity and selectivity diagnostic kits, and effective antiviral and protective therapeutics to decline and eliminate the viral load and side effects derived from tissue damages. Therefore, non-toxic antiviral nanoparticles (NPs) have been under development for clinical application to prevent and treat COVID-19. NPs showed great promise to provide nano vaccines against viral infections. Here, we discuss the potentials of NPs that may be applied as a drug itself or as a platform for the aim of drug and vaccine repurposing and development. Meanwhile, the advanced strategies based on NPs to detect viruses will be described with the goal of encouraging scientists to design effective and cost-benefit nanoplatforms for prevention, diagnosis, and treatment.
新冠病毒（COVID-19）最近已成为上世纪最具挑战性的大流行病之一，具有致命后果和高繁殖率。这凸显了设计有效疫苗以预防病毒感染、通过高灵敏度和选择性诊断试剂盒进行早期快速诊断以及使用有效的抗病毒和保护性疗法来降低和消除病毒载量以及组织损伤所产生副作用的迫切需求。因此，无毒抗病毒纳米颗粒（NPs）已在研发中，用于预防和治疗COVID-19的临床应用。纳米颗粒在提供针对病毒感染的纳米疫苗方面显示出巨大潜力。在此，我们讨论纳米颗粒作为药物本身或作为药物和疫苗重新利用与开发平台的潜力。同时，将描述基于纳米颗粒检测病毒的先进策略，目的是鼓励科学家设计有效且具有成本效益的纳米平台用于预防、诊断和治疗。
